Drugs.com Clinical Trial ResultsOriginal article
OncoC4 Receives FDA Fast Track Designation for Cesalatamig, an Investigational PD-1/VEGF Bispecific Antibody
RegulatoryCesalatamigPositive
AI Analysis
Summary
OncoC4 Inc. announced that the FDA granted Fast Track designation for Cesalatamig, an investigational PD-1/VEGF bispecific antibody for cancer treatment. Fast Track status accelerates the regulatory review process for the drug candidate.
Outcome Details
Fast Track designation granted
Importance:6/10
Sentiment:
0.70
FDAFast Trackoncologybispecific antibodyPD-1VEGF
Read the original article
Published by Drugs.com Clinical Trial Results on September 16, 2026 10:09 PM